tiprankstipranks

Matthew Singleton Insider Profile

4 Followers
Matthew Singleton, Director at Viking Therapeutics, holds 9.50K shares in Viking Therapeutics (Ticker: VKTX), holds 4.97K shares in Cubist Pharma (Ticker: CBST). Most recently, Matthew Singleton Bought ― shares of Viking Therapeutics on May 31, 2018 for an estimated value of 93.19K.
tipranks
Matthew Singleton

Matthew Singleton
Viking Therapeutics (VKTX)
Director

Not Ranked
Matthew Singleton has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$687K
100.00%
A breakdown of Matthew Singleton's holdings

Insider Roles

Viking Therapeutics
(VKTX)
Director
Roles that Matthew Singleton holds in companies

Most Profitable Insider Trade

Stock:
Viking Therapeutics
(VKTX)
Rating:Informative Buy
Date:May 31, 2018 - May 31, 2019
Return:-23.00%
The most profitable trade made by Matthew Singleton

Matthew Singleton's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Viking Therapeutics
May 31, 2018
Director
Informative Buy
93.19K
$687.33K
CBST
Cubist Pharma
Jun 11, 2013
Uninformative Buy
List of latest transactions for each holding click on a transaction to see Matthew Singleton's performance on stock

Matthew Singleton insider profile FAQ

What is the percentage of profitable transactions made by Matthew Singleton?
The percentage of profitable transactions made by Matthew Singleton is ―.
    What is the average return per transaction made by Matthew Singleton?
    The average return per transaction made by Matthew Singleton is ―.
      What stocks does Matthew Singleton hold?
      Matthew Singleton holds: VKTX, CBST stocks.
        What was Matthew Singleton’s latest transaction?
        Matthew Singleton latest transaction was an Informative Buy of $93.19K.
          What was Matthew Singleton's most profitable transaction?
          Matthew Singleton’s most profitable transaction was an Informative Buy of VKTX stock on May 31, 2018. The return on the trade was -23.00%.
            What is Matthew Singleton's role in Viking Therapeutics?
            Matthew Singleton's role in Viking Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.